Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).
Volume: 39, Issue: 6_suppl, Pages: 324 - 324
Published: Feb 20, 2021
Abstract
324 Background: Renal medullary carcinoma (RMC) is one of the most lethal renal cell malignancies with a median overall survival (OS) of only 13 months from diagnosis (Shah et al. BJU Int., 2017). RMC predominantly affects young individuals of African descent and is characterized by loss of the tumor suppressor SMARCB1 in all cases. Platinum-based chemotherapy produces a best response rate of 29% and is the recommended front line therapy for RMC...
Paper Details
Title
Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).
Published Date
Feb 20, 2021
Journal
Volume
39
Issue
6_suppl
Pages
324 - 324
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History